4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide,
D 4476,
D-4476,
D4476 cpd,
301836-43-1,
D4476,
CK1 Inhibitor,
D 4476,
casein kinase I inhibitor,
4-(4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide,
Casein Kinase I Inhibitor, D4476,
D-4476,
4-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide,
CHEMBL410456,
DPDZHVCKYBCJHW-UHFFFAOYSA-N,
Benzamide,4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-,
4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide,
InSolution™ Casein Kinase I Inhibitor, D4476,
C23H18N4O3,
4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl]benzamide,
4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide,
AC1O4WCQ,
K00227,
MLS006010815,
SCHEMBL373737,
GTPL5940,
CHEBI:91448,
CTK4G4622,
AOB6860,
DTXSID60423554,
EX-A538,
HMS3229C20,
HMS3266B22,
HMS3648M06,
HMS3677F18,
BCP09776,
3568AH,
BDBM50229971,
FD5005,
IN1394,
MFCD09037526,
s7642,
ZINC14806405,
AKOS024457325,
CCG-206826,
CCG-208141,
CS-1080,
QC-5031,
KS-0000181D,
NCGC00242498-01,
NCGC00242498-03,
4CA-0428,
AK544283,
BC600619,
D4476, >=98% (HPLC), solid,
HY-10324,
SMR004701747,
AB0087813,
FT-0700282,
W-5391,
D4476 (D-4476),
SR-01000946388,
J-017815,
SR-01000946388-1,
BRD-K09132007-001-01-8,
BRD-K09132007-001-04-2,
4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide,
4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)1H-imidazol-2-yl]benzamide,
4-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]-benzamide,
4-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1h-imidazol-2-yl]benzamide,
D00JGL,
D4476 cpd,
CID6419753,
A3342,
A13949,
C493177,
4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide,
Purvalanol A; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine,